Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07410312 · ClinicalTrials.gov registry record · Early Phase 1
BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction
A Early Phase 1 study, sponsored by Northwestern University.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT07410312 is a Early Phase 1 study that has not yet begun recruiting, run by Northwestern University. The registered enrollment target is 20 participants.
The verdict
NCT07410312, a Early Phase 1 study, has not yet begun recruiting, sponsored by Northwestern University.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will determine if primary graft dysfunction (which causes low blood oxygen levels and fluid or inflammation in the lungs) after lung transplant can be prevented through the use of the study drug (IL-1 receptor antagonist, Anakinra). In this study, lung transplant participants who are randomized to the treatment group will have the study drug injected into the solution that their donor lungs are kept in prior to transplant.
Interventions
- DRUG Anakinra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07410312
The ClinicalTrials.gov registry entry for NCT07410312 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anakinra is the first listed.
NCT07410312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07410312 about?
NCT07410312 is a clinical study titled "BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction". This study will determine if primary graft dysfunction (which causes low blood oxygen levels and fluid or inflammation in the lungs) after lung transplant can be prevented through the use of the study drug (IL-1 receptor antagonist, Anakinra). In this study, lung transplant participants who are rand...
What is the current status of trial NCT07410312?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2026-07-01. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07410312?
The interventions under investigation include: Anakinra (DRUG).
Who is sponsoring clinical trial NCT07410312?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.